FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Ghebeh, Hazem ^a   Barhoush, Eman ^a   Tulbah, Asma ^a   Elkum, Naser ^a   Al Tweigeri, Taher ^a   Dermime, Said ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; ESTROGEN RECEPTOR; PROTEIN PD 1; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN; CD274 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PDCD1 PROTEIN, HUMAN;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; PROTEIN TARGETING; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; BIOSYNTHESIS; BLOOD; BREAST TUMOR; CYTOLOGY; FEMALE; IMMUNOTHERAPY; LYMPH NODE METASTASIS; METABOLISM; METHODOLOGY; MIDDLE AGED; NEOPLASM; T LYMPHOCYTE;

ADULT; ANTIGENS, CD; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASMS; RECEPTORS, ESTROGEN; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 42049111164     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-57     Document Type: Article

References (57)

1. Ahmad M Rees RC Ali SA Escape from immunotherapy: Possible mechanisms that influence tumor regression/progression Cancer Immunology, Immunotherapy 2004, 53(10):844-854. 10.1007/s00262-004-0540-x
2. Rivoltini L Canese P Huber V Iero M Pilla L Valenti R Fais S Lozupone F Casati C Castelli C Parmiani G Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: How can we tilt the balance towards immune-mediated cancer control? Expert Opinion on Biological Therapy 2005, 5(4):463-476. 10.1517/ 14712598.5.4.463 15934826
3. Seliger B Strategies of tumor immune evasion Biodrugs 2005, 19(6):347-354. 10.2165/00063030-200519060-00002 16392887
4. Freeman GJ Long AJ Iwai Y Bourque K Chernova T Nishimura H Fitz LJ Malenkovich N Okazaki T Byrne MC Horton HF Fouser L Carter L Ling V Bowman MR Carreno BM Collins M Wood CR Honjo T Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 2000, 192(7):1027-1034. 10.1084/jem.192.7.1027 11015443
5. Dong H Zhu G Tamada K Chen L B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion Nat Med 1999, 5(12):1365-1369. 10.1038/70932 10581077
6. Dong H Strome SE Salomao DR Tamura H Hirano F Flies DB Roche PC Lu J Zhu G Tamada K Lennon VA Celis E Chen L Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion Nat Med 2002, 8(8):793-800. 12091876
7. Selenko-Gebauer N Majdic O Szekeres A Hofler G Guthann E Korthauer U Zlabinger G Steinberger P Pickl WF Stockinger H Knapp W Stockl J B7-H1 (programmed death-1 ligand) on dendritic cells is involved in the induction and maintenance of T cell anergy J Immunol 2003, 170(7):3637-3644. 12646628
8. Iwai Y Ishida M Tanaka Y Okazaki T Honjo T Minato N Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proc Natl Acad Sci USA 2002, 99(19):12293-12297. 129438 12218188 10.1073/pnas.192461099
9. Konishi J Yamazaki K Azuma M Kinoshita I Dosaka-Akita H Nishimura M B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression Clin Cancer Res 2004, 10(15):5094-5100. 10.1158/ 1078-0432.CCR-04-0428 15297412
10. Nomi T Sho M Akahori T Hamada K Kubo A Kanehiro H Nakamura S Enomoto K Yagita H Azuma M Nakajima Y Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer Clin Cancer Res 2007, 13(7):2151-2157. 10.1158/ 1078-0432.CCR-06-2746 17404099
11. Ohigashi Y Sho M Yamada Y Tsurui Y Hamada K Ikeda N Mizuno T Yoriki R Kashizuka H Yane K Tsushima F Otsuki N Yagita H Azuma M Nakajima Y Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer Clin Cancer Res 2005, 11(8):2947-2953. 10.1158/1078-0432.CCR-04-1469 15837746
12. Strome SE Dong H Tamura H Voss SG Flies DB Tamada K Salomao D Cheville J Hirano F Lin W Kasperbauer JL Ballman KV Chen L B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma Cancer Res 2003, 63(19):6501-6505. 14559843
13. Thompson RH Gillett MD Cheville JC Lohse CM Dong H Webster WS Krejci KG Lobo JR Sengupta S Chen L Zincke H Blute ML Strome SE Leibovich BC Kwon ED Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target Proc Natl Acad Sci U S A 2004, 101(49):17174-17179. 534606 15569934 10.1073/pnas.0406351101
14. Thompson RH Kuntz SM Leibovich BC Dong H Lohse CM Webster WS Sengupta S Frank I Parker AS Zincke H Blute ML Sebo TJ Cheville JC Kwon ED Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up Cancer Res 2006, 66(7):3381-3385. 10.1158/ 0008-5472.CAN-05-4303 16585157
15. Wintterle S Schreiner B Mitsdoerffer M Schneider D Chen L Meyermann R Weller M Wiendl H Expression of the B7-related molecule B7-H1 by glioma cells: A potential mechanism of immune paralysis Cancer Res 2003, 63(21):7462-7467. 14612546
16. Hamanishi J Mandai M Iwasaki M Okazaki T Tanaka Y Yamaguchi K Higuchi T Yagi H Takakura K Minato N Honjo T Fujii S Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer Proc Natl Acad Sci U S A 2007, 104(9):3360-3365. 1805580 17360651 10.1073/pnas.0611533104
17. Thompson RH Dong H Lohse CM Leibovich BC Blute ML Cheville JC Kwon ED PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma Clin Cancer Res 2007, 13(6):1757-1761. 10.1158/1078-0432.CCR-06-2599 17363529
18. Ghebeh H Mohammed S Al-Omair A Qattan A Lehe C Al-Qudaihi G Elkum N Alshabanah M Bin Amer S Tulbah A Ajarim D Al-Tweigeri T Dermime S The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors Neoplasia 2006, 8(3):190-198. 16611412 16611412 1578520 10.1593/neo.05733
19. Thornton AM Shevach EM CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production Journal of Experimental Medicine 1998, 188(2):287-296. 10.1084/jem.188.2.287 9670041
20. Ng WF Duggan PJ Ponchel F Matarese G Lombardi G Edwards AD Isaacs JD Lechler RI Human CD4(+)CD25(+) cells: A naturally occurring population of regulatory T cells Blood 2001, 98(9):2736-2744. 10.1182/ blood.V98.9.2736 11675346
21. Hori S Nomura T Sakaguchi S Control of regulatory T cell development by the transcription factor Foxp3. [see comment] Science 2003, 299(5609):1057-1061. 10.1126/science.1079490 12522256
22. Yagi H Nomura T Nakamura K Yamazaki S Kitawaki T Hori S Maeda M Onodera M Uchiyama T Fujii S Sakaguchi S Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells International Immunology 2004, 16(11):1643-1656. 10.1093/intimm/dxh165 15466453
23. Schreiber TH The Use of FoxP3 as a Biomarker and Prognostic Factor for Malignant Human Tumors Cancer Epidemiol Biomarkers Prev 2007, 16(10):1931-1934. 10.1158/1055-9965.EPI-07-0396 17932340
24. Curiel TJ Coukos G Zou L Alvarez X Cheng P Mottram P Evdemon-Hogan M Conejo-Garcia JR Zhang L Burow M Zhu Y Wei S Kryczek I Daniel B Gordon A Myers L Lackner A Disis ML Knutson KL Chen L Zou W Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival Nature Medicine 2004, 10(9):942-949. 10.1038/ nm1093 15322536
25. Liyanage UK Moore TT Joo HG Tanaka Y Herrmann V Doherty G Drebin JA Strasberg SM Eberlein TJ Goedegebuure PS Linehan DC Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma J Immunol 2002, 169(5):2756-2761. 12193750 12193750
26. Bates GJ Fox SB Han C Leek RD Garcia JF Harris AL Banham AH Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse Journal of Clinical Oncology 2006, 24(34):5373-5380. 10.1200/ JCO.2006.05.9584 17135638
27. Liang S Alard P Zhao Y Parnell S Clark SL Kosiewicz MM Conversion of CD4+ CD25- cells into CD4+ CD25+ regulatory T cells in vivo requires B7 costimulation, but not the thymus Journal of Experimental Medicine 2005, 201(1):127-137. 10.1084/jem.20041201 15630140 2212775
28. Krupnick AS Gelman AE Barchet W Richardson S Kreisel FH Turka LA Colonna M Patterson GA Kreisel D Murine vascular endothelium activates and induces the generation of allogeneic CD4+25+Foxp3+ regulatory T cells J Immunol 2005, 175(10):6265-6270. 16272276 16272276
29. Aramaki O Shirasugi N Takayama T Shimazu M Kitajima M Ikeda Y Azuma M Okumura K Yagita H Niimi M Programmed death-1-programmed death-L1 interaction is essential for induction of regulatory cells by intratracheal delivery of alloantigen Transplantation 2004, 77(1):6-12. 10.1097/01.TP.0000108637.65091.4B 14724428
30. Baecher-Allan C Brown JA Freeman GJ Hafler DA CD4+CD25high regulatory cells in human peripheral blood J Immunol 2001, 167(3):1245-1253. 11466340
31. Kitazawa Y Fujino M Wang Q Kimura H Azuma M Kubo M Abe R Li XK Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses Transplantation 2007, 83(6):774-782. 10.1097/01.tp.0000256293.90270.e8 17414712
32. Ghebeh H Tulbah A Mohammed S Elkum N Amer SM Al-Tweigeri T Dermime S Expression of B7-H1 in breast cancer patients is strongly associated with high proliferative Ki-67-expressing tumor cells Int J Cancer 2007. 17415709
33. Armstrong A Dermime S Developing effective cancer vaccines: Design and monitoring are critical Br J Cancer 2001, 84(11):1433-1436. 10.1054/ bjoc.2001.1839 11384088
34. Keir ME Liang SC Guleria I Latchman YE Qipo A Albacker LA Koulmanda M Freeman GJ Sayegh MH Sharpe AH Tissue expression of PD-L1 mediates peripheral T cell tolerance J Exp Med 2006, 203(4):883-895. 2118286 16606670 10.1084/jem.20051776
35. Blank C Gajewski TF Mackensen A Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy Cancer Immunol Immunother 2005, 54(4):307-314. 10.1007/s00262-004-0593-x 15599732
36. KK Moudgil KD Induction and maintenance of self tolerance: The role of CD4+CD25+ regulatory T cells Arch Immunol Ther Exp (Warsz) 2006, 54(5):307-321. 10.1007/s00005-006-0035-x 17031470
37. Beyer M Schultze JL Regulatory T cells in cancer Blood 2006, 108(3):804-811. 10.1182/blood-2006-02-002774 16861339
38. Leong PP Mohammad R Ibrahim N Ithnin H Abdullah M Davis WC Seow HF Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast Immunol Lett 2006, 102(2):229-236. 10.1016/j.imlet.2005.09.006 16246429
39. Chen W Jin W Hardegen N Lei KJ Li L Marinos N McGrady G Wahl SM Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 J Exp Med 2003, 198(12):1875-1886. 10.1084/jem.20030152 14676299
40. Walker MR Carson BD Nepom GT Ziegler SF Buckner JH De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25- cells Proc Natl Acad Sci U S A 2005, 102(11):4103-4108. 554797 15753318 10.1073/pnas.0407691102
41. Yang ZZ Novak AJ Stenson MJ Witzig TE Ansell SM Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma Blood 2006, 107(9):3639-3646. 1895773 16403912 10.1182/blood-2005-08-3376
42. Miller AM Lundberg K Ozenci V Banham AH Hellstrom M Egevad L Pisa P CD4+ CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients J Immunol 2006, 177(10):7398-7405. 17082659
43. Chang J Clark GM Allred DC Mohsin S Chamness G Elledge RM Survival of patients with metastatic breast carcinoma: Importance of prognostic markers of the primary tumor Cancer 2003, 97(3):545-553. 10.1002/ cncr.11083 12548595
44. Hilsenbeck SG Ravdin PM de Moor CA Chamness GC Osborne CK Clark GM Time-dependence of hazard ratios for prognostic factors in primary breast cancer Breast Cancer Res Treat 1998, 52(1-3):227-237. 10.1023/ A:1006133418245 10066085
45. Shipitsin M Campbell LL Argani P Weremowicz S Bloushtain-Qimron N Yao J Nikolskaya T Serebryiskaya T Beroukhim R Hu M Halushka MK Sukumar S Parker LM Anderson KS Harris LN Garber JE Richardson AL Schnitt SJ Nikolsky Y Gelman RS Polyak K Molecular definition of breast tumor heterogeneity Cancer Cell 2007, 11(3):259-273. 10.1016/j.ccr.2007.01.013 17349583
46. Marie JC Letterio JJ Gavin M Rudensky AY TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells J Exp Med 2005, 201(7):1061-1067. 10.1084/jem.20042276 15809351 2213134
47. Onizuka S Tawara I Shimizu J Sakaguchi S Fujita T Nakayama E Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody Cancer Res 1999, 59(13):3128-3133. 10397255
48. Keir ME Freeman GJ Sharpe AH PD-1 Regulates Self-Reactive CD8+ T Cell Responses to Antigen in Lymph Nodes and Tissues J Immunol 2007, 179(8):5064-5070. 17911591
49. Carter L Fouser LA Jussif J Fitz L Deng B Wood CR Collins M Honjo T Freeman GJ Carreno BM PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2 Eur J Immunol 2002, 32(3):634-643. 10.1002/ 1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9 11857337
50. Ahmadzadeh M Rosenberg SA IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients Blood 2006, 107(6):2409-2414. 1473973 16304057 10.1182/blood-2005-06-2399
51. Roncador G Brown PJ Maestre L Hue S Martinez-Torrecuadrada JL Ling KL Pratap S Toms C Fox BC Cerundolo V Powrie F Banham AH Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level Eur J Immunol 2005, 35(6):1681-1691. 10.1002/ eji.200526189 15902688
52. Barber DL Wherry EJ Masopust D Zhu B Allison JP Sharpe AH Freeman GJ Ahmed R Restoring function in exhausted CD8 T cells during chronic viral infection Nature 2006, 439(7077):682-687. 10.1038/nature04444 16382236
53. Zabala M Lasarte JJ Perret C Sola J Berraondo P Alfaro M Larrea E Prieto J Kramer MG Induction of immunosuppressive molecules and regulatory T cells counteracts the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer J Hepatol 2007, 1:1. 10.1007/s12072-007-5002-z
54. Curigliano G Spitaleri G Dettori M Locatelli M Scarano E Goldhirsch A Vaccine immunotherapy in breast cancer treatment: Promising, but still early Expert Rev Anticancer Ther 2007, 7(9):1225-1241. 10.1586/ 14737140.7.9.1225 17892423
55. Hirano F Kaneko K Tamura H Dong H Wang S Ichikawa M Rietz C Flies DB Lau JS Zhu G Tamada K Chen L Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res 2005, 65(3):1089-1096. 15705911
56. Dannull J Su Z Rizzieri D Yang BK Coleman D Yancey D Zhang A Dahm P Chao N Gilboa E Vieweg J Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells J Clin Invest 2005, 115(12):3623-3633. 1288834 16308572 10.1172/JCI25947
57. Webster WS Thompson RH Harris KJ Frigola X Kuntz S Inman BA Dong H Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine J Immunol 2007, 179(5):2860-2869. 17709500